Medicare Part D Spending on the EpiPen Increased More than 1000 Percent from 2007 to 2014 September 21, 2016 News Release As policymakers in Washington scrutinize the rising cost of the EpiPen auto-injector, a new analysis from the Kaiser Family Foundation shows that Medicare Part D spending for the potentially life-saving device increased by more than 1000 percent between 2007, the year after the Part D drug benefit took effect, and…
Web Event: Rx Drugs and the U.S. Health System – A Conversation about Election-Cycle Proposals for Lowering Costs October 5, 2016 Event On Wednesday, October 5, from noon to 1 p.m. ET, the Kaiser Family Foundation will host a web conversation to discuss proposals for controlling prescription drug costs, examine pros and cons of the ideas, and assess the likelihood that the plans will be enacted.
U.S. Global Health Policy One Year In to the Trump Administration January 29, 2018 News Release A new Kaiser Family Foundation issue brief assessing global health policy one year after President Trump took office finds half of Americans (54%) say they want the U.S. to play a major or leading role in improving health for people in developing countries, though support for such engagement is strongest among Democrats (73%)…
A Check Up on U.S. Global Health Policy, After One Year of the Trump Administration January 29, 2018 Issue Brief In this brief, we take stock of the U.S. global health response on the occasion of one year of the Trump Presidency and look ahead to the global health policy issues that are likely to be front and center in the coming months and years. We include a discussion of new KFF polling data (from January 2018) to provide an updated assessment of U.S. public support for global health programs.
What Could U.S. Budget Cuts Mean for Global Health? July 21, 2017 Issue Brief President Trump’s fiscal year 2018 budget request would cut global health programs by approximately $2.5 billion. This analysis models the potential impact of the Administration’s proposed budget, as well as two budget scenarios with more modest decreases.
How Much Has Medicare Spent on the EpiPen Since 2007? September 20, 2016 Issue Brief This data note examines the effects of rising EpiPen prices on Medicare and beneficiaries. We analyze EpiPen spending, in the aggregate and per user, in Medicare Part D between 2007 (the year after the Part D drug benefit took effect, and the year Mylan acquired the product) and 2014 (the most recent year of data available).
The Status of Funding for Zika: Comparing the President’s Request and Congressional Proposals September 6, 2016 News Release Zika, a mosquito-transmitted infection that in pregnant women can cause microcephaly as well as other serious birth defects, has recently become a global challenge, and with the first cases of local transmission now reported in the U.S., a domestic one as well. No new funding for Zika has yet been appropriated…
Key Implementers of U.S. Global Health Efforts September 6, 2016 Issue Brief This brief provides an overview of the implementing organizations that received U.S. global health funding from the U.S. Agency for International Development (USAID) in FY 2015.
Web Event: Rx Drugs and the U.S. Health System: A Conversation about Medicare Prescription Drug Costs September 7, 2016 Event On Wednesday, September 7, from noon to 1 p.m. ET, the Kaiser Family Foundation hosted a web conversation to discuss trends in Medicare prescription drug spending, as well as proposals to reduce costs and forecasts of what beneficiaries can expect in coming years.
The Role of NGOs in the U.S. Global Health Response July 21, 2015 Issue Brief This data note helps shed light on the role of non-governmental organizations (NGOs) in the U.S. global health response. Using updated data and building on earlier Kaiser Family Foundation reports, it paints a fuller picture of the role of these key implementers of U.S. global health programs and discusses key policy questions going forward.
